A clinical prediction rule for nerve function impairment in leprosy patients - Revisited after 5 years of follow-up

Leprosy Review

Volumn 74, Issue 1, 2003, Pages 35-41

  Croft, Richard P ^a,d   Nicholls, Peter G ^b   Steyerberg, Ewout W ^c   Richardus, Jan H ^c   Withington, Steven G ^a   Smith, W Cairns S ^b  

^a Danish Bangladesh Leprosy Mission   (Bangladesh)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHEMOTHERAPY; CHILD; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LEPROSY; MAJOR CLINICAL STUDY; MALE; MULTIBACILLARY LEPROSY; NERVE FUNCTION; NERVE INJURY; PAUCIBACILLARY LEPROSY; PREDICTION; RISK ASSESSMENT; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; COHORT STUDIES; CONFIDENCE INTERVALS; DISABILITY EVALUATION; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEPROSTATIC AGENTS; LEPROSY; MALE; MIDDLE AGED; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 0345700309     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Rose P, Waters MF. Reversal reactions in leprosy and their management. Lepr Rev, 1991; 62: 113-121.
2. Lienhardt C, Fine PE. Type 1 reaction, neuritis and disability in leprosy: what is the current epidemiological situation? Lepr Rev, 1994; 65: 9-33.
3. Van Brakel WH, Anderson AM. Impairment and disability in leprosy: in search of the missing link. Ind J Lepr, 1997; 69: 361-376.
4. Jiang J, Watson JM, Zhang GC, Wei XY. A field trial of detection and treatment of NFI in leprosy: report from national POD pilot project. Lepr Rev, 1998; 69: 367-375.
5. Croft RP, Richardus JH, Smith WCS. Field treatment of acute NFI in leprosy using a standardized corticosteroid regimen: first year's experience with 100 patients. Lepr Rev, 1997; 68: 316-325.
6. Croft RP, Nicholls PG, Steyerberg EW, Richardus JH, Smith WCS. A clinical prediction rule for nerve function impairment in leprosy patients. Lancet, 2000; 355: 1603-1606.
7. Croft RP, Nicholls PG, Richardus JH, Smith WCS. Nerve function impairment in leprosy: design, methodology and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev, 1999; 70: 140-159.
8. Croft RP, Nicholls PG, Richardus JH, Smith WCS. Incidence rates of acute NFI in leprosy: a prospective cohort analysis after 24 months. Lepr Rev, 2000; 71: 18-33.
9. Croft RP, Nicholls PG, Richardus JH, Smith WCS. The treatment of acute NFI in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev, 2000; 71: 154-168.
10. Watson JM. Essential action to minimise disability in leprosy patients. Leprosy Mission, London, 1986.
11. Anderson AM, Croft RP. Reliability of Semmes Weinstein monofilament and ballpoint sensory testing and VMT in Bangladesh. Lepr Rev, 1999; 70: 305-313
12. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med, 1996; 15: 361-387.
13. Steyerberg EW, Harrell FE, Borsboom GJ et al. Internal validation of prediction models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol, 2001; 54: 774-781.
14. Lockwood DNJ. Leprosy elimination - a virtual phenomenon or reality? BMJ, 2002; 324: 1516-1518.